Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of Pelareorep in combination with atezolizumab with or without chemotherapy in patients with advanced or metastatic GI tumors

Next Previous
Trial Profile

Phase I/II study of Pelareorep in combination with atezolizumab with or without chemotherapy in patients with advanced or metastatic GI tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Pelareorep (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Tipiracil/trifluridine
  • Indications Adenocarcinoma; Anal cancer; Colorectal cancer; Gastrointestinal cancer; Pancreatic ductal carcinoma; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GOBLET
  • Sponsors Oncolytics Biotech

Most Recent Events

  • 20 Jul 2026 According to an Oncolytics Biotech media release,the U.S. Food and Drug Administration has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal who have progressed on or were intolerant to one or more prior lines of systemic therapy. The designation is supported by results form this trial.
  • 22 May 2026 According to an Oncolytics Biotech media release, translational result data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, Illinois, from May 29-June 2, 2026.
  • 19 May 2026 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top